Clinical Study Highlights Detection of Fetal Trisomy 13 with the Harmony™ Prenatal Test

SAN JOSE, Calif., Sept. 24, 2012 /PRNewswire/ -- A new study published in the journal Ultrasound in Obstetrics and Gynecology, is the largest study to date of non-invasive prenatal testing (NIPT) for detecting fetal trisomy 13 (T13) and provides further evidence of the Harmony Prenatal Test's utility for detection of genetic conditions. T13 causes Patau syndrome and affects approximately one in 16,000 newborns. T13 is also associated with a high rate of spontaneous miscarriage. 

(Logo: http://photos.prnewswire.com/prnh/20120924/NE79343LOGO )

The study, available at http://onlinelibrary.wiley.com/doi/10.1002/uog.12299/abstract, was co-led by Dr. Kypros Nicolaides and his research staff of the Harris Birthright Research Centre and Ariosa Diagnostics. The study was conducted in two phases. The first phase was used to optimize the T13 algorithm – developed by Ariosa Diagnostics – which was then applied to an independent second group of patients. In the blinded analysis of the second group, of the ten fetal T13 cases, eight were given T13 risk scores greater than 99 percent with the Harmony test. Of the 1,939 non-T13 cases, all but one case was correctly classified as low-risk thereby yielding a false positive rate of less than 0.1 percent. All non-T13 cases were from an average-risk population.

"Given the rarity of trisomy 13, it is critical to have a test with as low of a false positive rate as possible," said Dr. Thomas Musci, vice president of clinical development and medical affairs at Ariosa Diagnostics. "Having studied the Harmony Prenatal Test in more than 6,000 women now, including over 2,000 average-risk women, NIPT represents a new option for pregnant women interested in prenatal testing for common trisomies."

The Harmony test represents the latest advance in prenatal testing. The test analyzes cell-free DNA circulating in maternal blood, which allows a high level of accuracy for detecting fetal trisomies. The test involves a single standard blood draw performed as early as 10 weeks' gestation.   

About Ariosa Diagnostics

Ariosa Diagnostics, Inc., is a molecular diagnostics company committed to innovating together to improve patient care.  The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com.

SOURCE Ariosa Diagnostics, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED